| Name | Ondine Biomedical Inc. NPV (CDI) |
|---|---|
| Epic | OBI |
| Isin | CA68234M2058 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 11.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £44.44 | Debt ratio | n/a |
| Shares in issue | 404.00 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -558.04 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -7 | 52-week high / low | 5.13p / 11.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Ondine Biomedical Inc. NPV (CDI) |
|---|---|
| Address | 888 - 1100 Melville Street, Vancouver, British Columbia, Canada, V6E 4A6 |
| Telephone | +1 604 669 0555 |
| Website | https://ondinebio.com/ |
| Director | Position |
|---|---|
| Ms Carolyn Cross | CEO |
| Mr Jean Charest | Chairman |
| Mr Craig Tooman | Non-Executive Director |
| Mr Michael Farrar | Non-Executive Director |
| Mr Nicolas Loebel | Chief Technology Officer |
| Ms Jean Duvall | Senior Independent Non-Executive Director |
| Dr Junaid Bajwa | Independent Non-Executive Director |
| Dr Simon Sinclair | Independent Non-Executive Director |
| Mr Kwong Choo | Interim CFO |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.98 | 1.44 | 0.64 |
| Inventory / work in progress | 1.07 | 1.29 | 1.06 |
| Trade and other receivables | 0.55 | 0.56 | 2.08 |
| Cash and equivalents | 2.98 | 13.12 | 30.36 |
| Other current assets and asset held for resale | 0.16 | 0.15 | n/a |
| Total of all assets | 5.73 | 16.57 | 34.14 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 3.49 | 3.91 | 3.92 |
| Long term liabilities | 0.16 | 1.02 | 0.56 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 3.65 | 4.92 | 4.48 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 2.08 | 11.64 | 29.66 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 239.65 | 235.04 | 235.04 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -266.33 | -251.92 | -232.54 |
| Share premium account | n/a | n/a | 10.53 |
| Total equity | 2.08 | 11.64 | 29.66 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -14.8 | -18.76 | -17.52 |
| Pre-tax profit | -14.41 | -19.37 | -50.09 |